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Tirofiban, an antagonist of the glycoprotein IIb/ 
/IIIa receptor, is indicated for the treatment of acute 
coronary syndrome (ACS), in combination with 
heparin. Tirofiban has been shown to decrease the 
rate of death in myocardial infarction and refractory 
ischemia patients.
Herein is presented the case of a 41-year- 
-old active smoker, transferred to our hospital for 
anterior ST-segment elevation myocardial infarc-
tion (Fig. 1A). Loading doses of acetylsalicylic 
acid (500 mg), prasugrel (60 mg) and 5000 UI 
of heparin were administered during transfer. 
Coronary angiogram demonstrated plaque rupture 
in the proximal left anterior descending artery 
(LAD) (Fig. 1B), associated with heavy thrombus 
burden visualized on optical coherence tomog-
raphy (Fig. 1C). A high dose bolus of tirofiban 
(25 µg/kg) followed by a continuous infusion (0.1 µg/ 
/kg/min) was administered and percutaneous coro-
nary intervention of LAD was performed with two 
drug eluting stents (Fig. 1D). Three hours after 
initiation of tirofiban administration, the patient 
developed bilateral severe subconjunctival hem-
orrhage (Fig. 1E) associated with blurred vision, 
prompting interruption of tirofiban perfusion. 
In this setting, de-escalation of P2Y12 inhibitor 
therapy was performed, prasugrel was switched 
for clopidogrel. The patient thrombocyte count was 
within normal range. Cardiac and ophthalmologic 
clinical evolution were favorable. According to 
available research, this is the first report of severe 
subconjunctival hemorrhage occurring as a com-
plication of tirofiban administration.
Potent platelet inhibition for patients present-
ing ACS has consistently been associated with 
a reduction of major adverse cardiac events. Accord-
ing to the most recent European Society of Cardiol-
ogy revascularization guidelines, dual antiplatelet 
therapy associating acetylsalicylic acid and ticagrelor 
or prasugrel is recommended for patients presenting 
ACS. Glycoprotein IIb/IIIa inhibitors can be used as 
an adjunctive therapy during percutaneous coronary 
intervention in cases of high thrombus burden. 
Hemorrhagic complications need to be addressed 
with caution, justifying individualized tailored anti-
platelet therapy adaptations when warranted.
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Figure 1. A. Admission electrocardiogram demonstrating anterior ST-segment elevation myocardial infarction; 
B. Coronary angiogram demonstrating a hazy lesion in the proximal left anterior descending artery (LAD); C. Intra-
coronary imaging by means of optical coherence tomography, demonstrating plaque rupture on the level of the 
proximal LAD; D. Coronary angiogram after percutaneous coronary intervention of the LAD with two drug eluting 
stents; E. Bilateral severe subconjunctival hemorrhage, developed 3 hours after initiation of tirofiban administration.
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